Publications by authors named "D Meredith"
Article Synopsis
- Molecular features, particularly CDKN2A/B loss, impact survival outcomes in IDH1/2-mutant astrocytomas, with grade 2/3 tumors showing varied survival based on molecular characteristics.
- In a study of 998 patients, those with intact CDKN2A/B and no focal amplifications had the longest survival, while variations in CDKN2A/B status correlated with poorer outcomes, particularly in grade 4 tumors.
- The research highlights the potential for improved prognostic predictions in IDHmut-astrocytomas by integrating molecular data with histological grading, revealing distinct profiles linked to survival outcomes.
Purpose: Radiation therapy may enhance anti-tumor immune responses by several mechanisms including induction of immunogenic cell death. We performed a phase 2 study of pembrolizumab with re-irradiation in patients with recurrent glioblastoma.
Methods: Sixty recurrent glioblastoma patients received pembrolizumab with re-irradiation alone (cohort A, bevacizumab-naïve; n=30) or with bevacizumab continuation (cohort B, n=30).
Article Synopsis
- The study explored the effect of perampanel, an AMPA receptor antagonist, on reducing hyperexcitability around gliomas, which could promote tumor growth.
- An open-label trial compared perampanel with standard care in patients with high-grade glioma undergoing surgery, measuring outcomes like high-frequency oscillation rates and seizure occurrence.
- Results showed no significant difference in hyperexcitability outcomes between perampanel and standard care, and early termination of the trial indicated similar seizure rates and overall survival for both treatments.
Background: Tractors and quad bikes pose a significant risk of fatal injuries among farmers, particularly affecting older farmers. This study aimed to explore the barriers and facilitators to the adoption of machine related safety behaviors among older farmers in Irish farm settings.
Method: Four focus groups were conducted via Zoom in February 2021.
Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma.
J Clin Endocrinol Metab
September 2024
Article Synopsis
- The study aims to uncover genetic changes linked to prolactinomas, ultimately identifying a mutation (ESR1Y537S) in an aggressive case of this tumor type at Brigham and Women's Hospital.
- A group of twenty patients was analyzed using advanced sequencing techniques, revealing the ESR1Y537S mutation in a post-menopausal woman, which is known to enhance estrogen receptor activity without needing a hormone trigger.
- The discovery of this mutation allowed for targeted treatment with elacestrant, in combination with radiotherapy, effectively managing tumor growth and significantly lowering prolactin levels in the patient.